Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SLIT-ROBO Rho GTPase-activating protein 1 (SRGAP1)
- Target
- SRGAP1
- Molecular classification
- Enzyme (specifically Rho GTPase-activating protein, ARHGAP family), Signal transduction modulator, Adapter/scaffolding protein (contains F-BAR, RhoGAP, SH3 domains)
01
Overview
SLIT-ROBO Rho GTPase-activating protein 1 (SRGAP1) is a multidomain enzyme and scaffolding protein within the ARHGAP family that modulates actin cytoskeleton dynamics by inactivating Rho GTPases, particularly CDC42 and possibly Rac1. It is recruited to sites of cell protrusion and junctions, where it mediates actin remodeling, cell migration, and axon guidance through interaction with the transmembrane receptor ROBO1 in the neuronal Slit-Robo signaling pathway. SRGAP1 has documented roles in neural development, epithelial junction maturation, and cell motility, and is increasingly implicated in cancer pathogenesis and certain developmental disorders because of its regulatory effects on cell movement and adhesion. No drugs are clinically validated to target SRGAP1, and no clinical biomarkers or safety data are established for pharmacological modulation of this protein.
- Other names
- ARHGAP13KIAA1304Rho GTPase-activating protein 13srGAP1NMTC2
02
Mechanism of action
Not applicable (as no drugs specifically target this protein)
03
Biological functions
Negative regulation of neuronal migration (via CDC42/Rac1 inactivation)Modulation of actin cytoskeleton dynamics and cellular protrusionsRegulation of cell adhesion and cell–cell junctionsDownstream effector of Slit-Robo signaling (neuronal guidance, morphogenesis)Modulation of cell migration and invasion
04
Disease associations
Cancer (implicated in ovarian, gastric, glioblastoma, hepatocellular carcinoma)Congenital anomalies (kidney and urinary tract via SLIT2-ROBO2 pathway)Thyroid cancer (nonmedullary, follicular thyroid carcinoma)Other developmental and neurological disorders
05
Safety considerations
Not directly applicable; safety concerns would be theoretical and relate to disruption of crucial neuronal and cytoskeletal functions, affecting migration, adhesion, and possibly development
Beyond the preview
Go deeper on SLIT-ROBO Rho GTPase-activating protein 1 (SRGAP1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SLIT-ROBO Rho GTPase-activating protein 1 (SRGAP1).